
<h4>Secondary Outcomes</h4>
<a id="article1.body1.sec3.sec3.p1" name="article1.body1.sec3.sec3.p1"></a><p>Ninety-five percent of children had cleared their parasite by day 2 in the ART+SP group compared to 35% for SP, 47% for CQ+SP, and 55% for AQ+SP (p&lt;0.001 for each comparison with AQ+SP). By days 3 and 7, there were no differences between the three combination therapies and they were all superior to SP alone, p = 0.005. In the SP group, there was no association between the day 0 parasitaemia and time to parasite clearance or between day 0 parasitaemia and clinical outcome. Fever resolution was slower with SP alone; the percentage of children who still had fever on day 1 were 18% for SP, 5% for CQ+SP, 6% for ART+SP and 5% for AQ+SP (p&lt;0.008 for each comparison with SP).</p>
<a id="article1.body1.sec3.sec3.p2" name="article1.body1.sec3.sec3.p2"></a><p>Mean haemoglobin concentration rose in all treatment groups. Compared to SP alone, the adjusted mean on day 14 was greater after CQ+SP (p = 0.03) and AQ+SP (p = 0.002) but not after ART+SP (p = 0.81). Gametocytes were present on day 0 in 73 (16%) children, <a href="#pone-0001578-t001">table 1</a>. There were no differences between the groups in the percentage of children with gametocytes on day 28; 4% after SP, 7% after CQ+SP, 5% after ART+SP and 7% after AQ+SP.</p>


<h4>Safety and Tolerability</h4>
<a id="article1.body1.sec3.sec4.p1" name="article1.body1.sec3.sec4.p1"></a><p>284 clinical AEs were reported in 185 children. Cough was commonest, making up 45% of all AEs. Compared to SP alone, cough was more commonly reported after ART+SP, p = 0.04. No other statistically significant differences were found. There were 8 serious adverse events (SAEs) in the study with no more than 4 in any treatment group. There were no deaths. The SAEs included 2 cases of pneumonia requiring intravenous antibiotics, 1 child with gastroenteritis requiring intravenous fluids and 5 treatment failures requiring hospitalisation for intravenous quinine. For two of these children, this was due to the occurrence of seizures shortly after receiving their medication on day 0 (1 AQ+SP, 1 CQ+SP), and 1 child had persisted vomiting on day 1 and was unable to continue oral treatment (AQ+SP). The other two children had early treatment failures (1 SP, 1 AQ+SP), and were too unwell to continue oral therapy.</p>
<a id="article1.body1.sec3.sec4.p2" name="article1.body1.sec3.sec4.p2"></a><p>Neutrophil counts fell after treatment in all treatment groups but the proportion of children with neutrophil counts of ≤0.5×10<sup>3</sup>/µl on day 14 (having been ≥1.0×10<sup>3</sup>/µl on recruitment) was greatest in the AQ+SP group (11.5%, n = 7), higher than the SP alone group (1.5%, n = 1), p = 0.03. For 17 of the 19 children in which this low neutrophil count was observed, a repeat sample between day 28 and 42 showed neutrophils ≥1.0×10<sup>3</sup>/µl. For the remaining 2 children no further sample was obtained. We noted no evidence of any ill effects due to these transient low neutrophil counts.</p>
<a id="article1.body1.sec3.sec4.p3" name="article1.body1.sec3.sec4.p3"></a><p>Two children in the AQ+SP treatment group developed plasma ALT levels on day 14 greater than three times the upper limit of normal having been in the normal range (15–45 U/L) on recruitment. The possible association of this adverse effect with AQ+SP was not significant, p = 0.24. One of these children had a day 14 ALT of 1540 U/L with a total bilirubin of 1.1 mg/dl (0.1–1.4 mg/dl). By day 42 the ALT had returned to normal. The other child had a day 14 ALT of 473 U/L with a total bilirubin of 2.2 mg/dl. No further samples were collected for analysis. Both children were well and completed 42 days of follow up and both had day 14 neutrophil counts ≥1.0×10<sup>3</sup>/µl.</p>


<h4>Selection of Resistance</h4>
<a id="article1.body1.sec3.sec5.p1" name="article1.body1.sec3.sec5.p1"></a><p>The resistance mutations <em>pfcrt</em> 76T, <em>dhfr</em> 164L and <em>dhps</em> 581G were detected in none of the pre-treatment (n = 244, 155 and 134 respectively) or post-treatment (n = 151,145 and 95) infections. <em>Pfmdr1</em> 86N (wild type) parasites were present in 219 out of 244 (89.8%) of pre-treatment infections and in 88.1% (134 out of 152) post-treatment infections. Within each treatment group, there was no difference in the proportions of wild and mutant alleles before and after treatment. When comparing between treatment groups, the proportions of <em>pfmdr1</em> 86Y (mutant) in the post treatment AQ+SP group (in 4 recrudescences and 1 new infection) was higher than in the SP post-treatment group, p = 0.002. <em>Pfmdr1</em> 1246D (wild type) parasites were present in 224 out of 231 (97%) of pre-treatment infections and in 94.5% (86 out of 91) post-treatment infections. This difference was not significant, and there were no differences within or between the four different treatment groups.</p>
<a id="article1.body1.sec3.sec5.p2" name="article1.body1.sec3.sec5.p2"></a><p>The prevalence of <em>dhfr</em> mutant alleles was very high in pre-treatment parasites; 99% (156/157) were 108N, 99.5% (254/255) were 51I and 96% (357/371) were 59R. <em>Dhps</em> mutants were also common pre-treatment; 97% (33/34) were 437G and 95.1% (355/373) were 540E. Pre-treatment, 91.6% (339 out of 370) of parasites were “quintuple” mutants (all mutant alleles at <em>dhfr</em> codons 51, 59 and 108 and <em>dhps</em> codons 437 and 540) and post-treatment, this figure was 92% (139/151). Paired analysis of parasites, pre and post treatment, showed no significant differences within or between the treatment groups.</p>

</div>

<div id="section4" class="section"><a id="s4" name="s4" toc="s4" title="Discussion"></a><h3>Discussion</h3>
<h4>Interpretation</h4>
<a id="article1.body1.sec4.sec1.p1" name="article1.body1.sec4.sec1.p1"></a><p>Ten years after the introduction of SP as first line treatment for uncomplicated malaria in Malawi the day 28 ACPR rate lies below 30%. Over 90% of pre-treatment parasites were “quintuple” mutants; this genotype has been shown to be strongly predictive of SP failure in young children in Malawi <a href="#pone.0001578-Kublin2">[16]</a>. Malawi is in the process of implementing its new treatment policy of artemether-lumefantrine and our data support the decision to abandon SP. This artemisinin-based combination therapy is highly effective and costs around $1 for an adult course. However, it is a relatively complex regime, 6 doses over 3 days with food, and until recently in Africa, supplies of the drug have not matched the huge demand.</p>
<a id="article1.body1.sec4.sec1.p2" name="article1.body1.sec4.sec1.p2"></a><p>Low cost alternatives to artemether-lumefantrine might have been attractive to the Malawi authorities and AQ+SP was one of the combinations considered. In most countries in Africa, antimalarials are obtained without prescription and often taken unnecessarily <a href="#pone.0001578-Abuya1">[17]</a>. In the era of ACTs, such unregulated use will be hard to sustain. Four other fixed ratio ACTs are in development, AQ plus ART is now available in Africa, chlorproguanil-dapsone plus ART has finished phase III testing, and will be submitted to the regulatory authorities in 2008, and piperaquine plus dihyroartemisinin and pyronaridine plus ART are well into phase III trials. Each of these is likely to be cheaper and more practicable to use than artemether-lumefantrine but still likely to be more expensive that AQ+SP or CQ+SP.</p>
<a id="article1.body1.sec4.sec1.p3" name="article1.body1.sec4.sec1.p3"></a><p>This study confirms the return of CQ sensitivity in Malawi and importantly, shows no evidence of the re-emergence of <em>pfcrt</em> 76T after treatment with CQ or AQ based combinations. The CQ+SP day 28 PP ACPR rate was 86%, lower than the rate of 99% reported from another randomised study in 2005, also in Blantyre, in which CQ was used as a monotherapy in 80 children with uncomplicated malaria <a href="#pone.0001578-Laufer1">[2]</a>. The children in our study were younger, mean age 22.2 vs. 31.2 months, and had higher parasite counts on enrolment, and this may explain some of this difference. Another possible reason, especially in the absence of <em>pfcrt</em> 76T mutants, is that some children in this study may have failed to achieve therapeutic CQ concentrations. A pharmacokinetic (PK) study was nested within this study and data on drug levels will be reported elsewhere.</p>
<a id="article1.body1.sec4.sec1.p4" name="article1.body1.sec4.sec1.p4"></a><p>AQ+SP was significantly more efficacious than CQ+SP, ART+SP and SP alone. AQ+SP also appears to have a longer period of post-treatment prophylaxis than the other treatments; reinfection rates on days 14, 28 and 42 were similar after treatment with SP, CQ+SP or ART+SP but with AQ+SP, no reinfections were seen until after day 28 (<a href="#pone-0001578-g002">figure 2</a>). AQ+SP was more efficacious than CQ+SP against a background of 100% <em>pfcrt</em> 76 wild type parasites. In vitro, AQ has greater activity against <em>P. falciparum</em> than CQ <a href="#pone.0001578-Hawley1">[18]</a>, and this greater potency may be evident here. Alternatively, the lower CQ+SP efficacy may have PK basis and data from the PK study will be used to address this. Treatment with AQ+SP was associated with the selection of parasites with the <em>pfmdr1</em> 86Y mutation between day 28 and day 42 after treatment.</p>
<a id="article1.body1.sec4.sec1.p5" name="article1.body1.sec4.sec1.p5"></a><p>The combination of ART+SP for 3 days was the least effective of the three combination therapies. This is not surprising given the poor efficacy of SP. As a monotherapy, ART is usually taken for 7 days; a 3-day ACT course is only efficacious when the second drug retains adequate efficacy. The combination of ART+SP has proven ineffective in other sites in Africa with significant background SP resistance <a href="#pone.0001578-Dorsey1">[19]</a>, <a href="#pone.0001578-Rwagacondo1">[20]</a>. This study highlights the importance of continuing follow up beyond 14 days; ART+SP had a 93% day 14 ACPR rate and had the fastest parasite clearance rate but efficacy by days 28 and 42 was poor.</p>


<h4>Generalizability and Overall evidence</h4>
<a id="article1.body1.sec4.sec2.p1" name="article1.body1.sec4.sec2.p1"></a><p>AQ+SP has shown excellent efficacy in several African studies and a recent meta-analysis concluded that the efficacy of AQ+SP in Africa was similar to that of AQ+ART but inferior to artemether-lumefantrine <a href="#pone.0001578-Obonyo1">[5]</a>.The results of these studies showed considerable variability, in part due to differences in existing background resistance to SP and AQ and also to differences in the transmission intensities at the study sites; AQ+SP was more efficacious in high transmission areas. This is probably due to increased host acquired immunity in these areas and also to the post-treatment prophylactic properties of the combination. AQ is a pro-drug, but its active metabolite desethyl AQ has a half-life of several weeks, similar to chloroquine and sulfadoxine. However, post-treatment prophylaxis comes at a cost; drugs with long terminal elimination phases promote the selection of parasites with resistance-conferring mutations <a href="#pone.0001578-Watkins1">[21]</a>. As the drug concentration falls to sub-therapeutic levels, recrudescent or newly infecting parasites carrying resistance mutations may be preferentially selected. This is especially important in areas of moderate to high transmission where re-infections are common and parasite densities may be high.</p>
<a id="article1.body1.sec4.sec2.p2" name="article1.body1.sec4.sec2.p2"></a><p>We saw evidence of the selection of the <em>pfmdr1</em> 86Y mutation after treatment with AQ+SP. This mutation is associated with in vivo AQ resistance <a href="#pone.0001578-Happi1">[22]</a>. Other studies have demonstrated the selection of <em>pfmdr1</em> 86Y and <em>pfmdr1</em> 1246Y mutations after treatment with AQ+ART <a href="#pone.0001578-Humphreys1">[23]</a>, <a href="#pone.0001578-Nsobya1">[24]</a>, and after treatment with AQ+SP <a href="#pone.0001578-Zongo1">[25]</a>. Studies from Zanzibar and Uganda have demonstrated significant increases in parasites carrying the <em>pfmdr1</em> 86N allele after treatment with artemether-lumefantrine <a href="#pone.0001578-Dokomajilar1">[26]</a>, <a href="#pone.0001578-Sisowath1">[27]</a>. This allele has been associated with decreased lumefantrine sensitivity in vitro <a href="#pone.0001578-Duraisingh1">[28]</a>. These studies provide evidence that these combination therapies are able to drive the selection of resistance mutations and it will be important to monitor closely their efficacy, especially in high transmission areas, to see whether these genotypic changes translate into treatment failures. Artemisinins have short half lives (measured in hours) while all of the companion drugs (apart from chlorproguanil-dapsone) in ACTs recommend by the WHO or under development have half-lives in the order of weeks. Whether the combination chlorproguanil-dapsone plus ART, in which both component drugs have short (closer matched) half-lives, will prevent this selection process, remains to be seen.</p>
<a id="article1.body1.sec4.sec2.p3" name="article1.body1.sec4.sec2.p3"></a><p>We were unable to detect <em>dhfr</em> 164L mutants using conventional PCR. This mutation is associated with failure of chlorproguanil-dapsone. One group, using real time PCR, has reported this mutation in 4 of 85 (4.7%) samples from pregnant women in Blantyre collected in 2003 <a href="#pone.0001578-Alker1">[29]</a>. We were unable to detect any <em>dhfr</em> 164L mutants in 158 samples collected in this study using a modified version of the same method, suggesting that if the mutation is present in this region, it remains extremely rare (Ochong E <em>et al</em>, in preparation).</p>
<a id="article1.body1.sec4.sec2.p4" name="article1.body1.sec4.sec2.p4"></a><p>AQ was withdrawn as a prophylaxis against malaria in 1986, because of agranulocytosis (1 in 2,100 subjects) and hepatitis (1 in 15,650) <a href="#pone.0001578-PhillipsHoward1">[30]</a>. These AEs have not been reported when AQ has been taken as malaria treatment. Between 1984 and 1987, 20 cases of AQ associated agranulocytosis were reported in the literature in individuals taking AQ for malaria prophylaxis <a href="#pone.0001578-Hatton1">[8]</a>, <a href="#pone.0001578-Neftel1">[9]</a>, <a href="#pone.0001578-Douer1">[31]</a>–<a href="#pone.0001578-Ellis1">[34]</a>. The shortest duration of prophylaxis prior to diagnosis of agranulocytosis was 3 weeks and lowest total dose consumed 1.2 grams. The treatment dose for a 70 kg adult is 2.1 grams. Neutrophil counts fell after treatment in all treatment groups in this study but the proportion of children with neutrophil counts of ≤0.5×10<sup>3</sup>/µl on day 14 was higher in the AQ+SP group than the SP alone group, p = 0.03. We also observed marked rises in ALT in 2 children after treatment with AQ+SP though this association was not found to be significant. These observations involve small numbers of children and the study was not powered to detect rare AEs. We do however think that given the track record of safety issues with AQ, these observations require further scrutiny especially as AQ may be used increasingly in African patients who have several episodes of malaria each year.</p>
<a id="article1.body1.sec4.sec2.p5" name="article1.body1.sec4.sec2.p5"></a><p>SP has failed in Malawi after a decade of useful service, and its role in intermittent presumptive therapy in pregnancy (IPT) should also now be re-evaluated. There has been a return of CQ sensitivity in Malawi, and CQ could be considered as a possible replacement for SP in IPT programmes. The potential for CQ to be used as part of combination therapy should be considered with caution unless and until CQ-sensitive parasites predominate throughout the region. Given the extensive cross-border movement of people, it seems likely that CQ-resistant parasites from neighbouring countries would be selected rapidly on redeployment of this drug.</p>
<a id="article1.body1.sec4.sec2.p6" name="article1.body1.sec4.sec2.p6"></a><p>The combination AQ+SP was highly efficacious, despite the low efficacy of SP alone; however, we found evidence that in these circumstances AQ may exert selective pressure for resistance mutations many weeks after treatment. In parts of West Africa where SP and AQ both remain efficacious, the combination AQ+SP could be considered for first line treatment for uncomplicated malaria. The drugs have similar pharmacokinetic profiles and the combination may offer a cheaper, longer lasting and readily available alternative to ACTs, with the benefit of longer post-treatment prophylaxis. AQ+ART is being increasingly used and it will be interesting to see whether this combination, with its mismatched kinetics, can prevent the development of AQ resistance. In addition, it will be important to monitor for potential toxicities of AQ after repeated treatment doses.</p>

</div>

<div id="section5" class="section"><a id="s5" name="s5" toc="s5" title="Supporting Information"></a><h3>Supporting Information</h3><div class="figshare_widget" doi="10.1371/journal.pone.0001578"></div><a name="pone.0001578.s001" id="pone.0001578.s001"></a><p class="siTitle"><strong><a href="/article/fetchSingleRepresentation.action?uri=info:doi/10.1371/journal.pone.0001578.s001">Checklist S1. </a></strong></p><a id="article1.body1.sec5.supplementary-material1.caption1.p1" name="article1.body1.sec5.supplementary-material1.caption1.p1"></a><p class="preSiDOI">CONSORT Checklist</p>
<p class="siDoi">doi:10.1371/journal.pone.0001578.s001</p><a id="article1.body1.sec5.supplementary-material1.caption1.p2" name="article1.body1.sec5.supplementary-material1.caption1.p2"></a><p class="postSiDOI">(0.06 MB DOC)</p>
<a name="pone.0001578.s002" id="pone.0001578.s002"></a><p class="siTitle"><strong><a href="/article/fetchSingleRepresentation.action?uri=info:doi/10.1371/journal.pone.0001578.s002">Protocol S1. </a></strong></p><a id="article1.body1.sec5.supplementary-material2.caption1.p1" name="article1.body1.sec5.supplementary-material2.caption1.p1"></a><p class="preSiDOI">Original study protocol as submitted to the Malawi Research Ethics Committee for approval</p>
<p class="siDoi">doi:10.1371/journal.pone.0001578.s002</p><a id="article1.body1.sec5.supplementary-material2.caption1.p2" name="article1.body1.sec5.supplementary-material2.caption1.p2"></a><p class="postSiDOI">(0.07 MB DOC)</p>
</div>





<div><a id="ack" name="ack" toc="ack" title="Acknowledgments"></a><h3>Acknowledgments</h3>
<a id="article1.back1.ack1.p1" name="article1.back1.ack1.p1"></a><p>The authors would like to thank the children and their parents for taking part in this study and the study team, Alice Mbekyani, Rose Paligolo, Mary Kandapo, Albert Malenga, Joseph Bwanali, Andrew Khoriyo and David Misomali for their hard work. We would also like to thank the District Health Officer for permission to site the study at Chileka Health Centre and all the other staff at the health centre. Thank you to Dr Sarah White for her statistical advice and supervision of MM and to John White for generation of the study randomisation code. We are indebted to Drs Shaf Ahmed, Frank Bell and Grace Malenga as the study Safety Management Committee and to Dr Neena Bodasing for acting as the study monitor.</p>
</div><div class="contributions"><a id="authcontrib" name="authcontrib" toc="authcontrib" title="Author Contributions"></a><h3>Author Contributions</h3><p>Conceived and designed the experiments: CP EZ MM SW DB PW. Performed the experiments: DB SN. Analyzed the data: DB MM. Contributed reagents/materials/analysis tools: CP SW MM. Wrote the paper: CP EZ MM SW DB PW.</p></div><div><a id="references" name="references" toc="references" title="References"></a><h3>References</h3><ol class="references"><li><span class="label">1.
              </span><a name="pone.0001578-Plowe1" id="pone.0001578-Plowe1"></a>Plowe CV, Kublin JG, Dzinjalamala FK, Kamwendo DS, Mukadam RA, et al.  (2004) Sustained clinical efficacy of sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Malawi after 10 years as first line treatment: five year prospective study. BMJ  328: 545.  <ul class="find" data-citedArticleID="1053886" data-doi="10.1136/bmj.37977.653750.ee"><li><a href="http://dx.doi.org/10.1136/bmj.37977.653750.ee" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Sustained+clinical+efficacy+of+sulfadoxine-pyrimethamine+for+uncomplicated+falciparum+malaria+in+Malawi+after+10+years+as+first+line+treatment%3A+five+year+prospective+study." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Sustained+clinical+efficacy+of+sulfadoxine-pyrimethamine+for+uncomplicated+falciparum+malaria+in+Malawi+after+10+years+as+first+line+treatment%3A+five+year+prospective+study.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">2.
              </span><a name="pone.0001578-Laufer1" id="pone.0001578-Laufer1"></a>Laufer MK, Thesing PC, Eddington ND, Masonga R, Dzinjalamala FK, et al.  (2006) Return of chloroquine antimalarial efficacy in Malawi. N Engl J Med  355: 1959–1966.  <ul class="find" data-citedArticleID="1053872" data-doi="10.1056/nejmoa062032"><li><a href="http://dx.doi.org/10.1056/nejmoa062032" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Return+of+chloroquine+antimalarial+efficacy+in+Malawi." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Return+of+chloroquine+antimalarial+efficacy+in+Malawi.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">3.
              </span><a name="pone.0001578-World1" id="pone.0001578-World1"></a>World Health Organisation (2006) Guidelines for the treatment of malaria.   <ul class="find-nolinks"></ul></li><li><span class="label">4.
              </span><a name="pone.0001578-Olumese1" id="pone.0001578-Olumese1"></a>Olumese P (2007) Antimalarial treatment policies for <em>P.falciparum</em> and <em>P.vivax</em> by country in WHO Africa region.   <a href="http://www.who.int/malaria/amdp/amdp_afro.htm">http://www.who.int/malaria/amdp/amdp_afr​o.htm</a>.  <ul class="find-nolinks"></ul></li><li><span class="label">5.
              </span><a name="pone.0001578-Obonyo1" id="pone.0001578-Obonyo1"></a>Obonyo CO, Juma EA, Ogutu BR, Vulule JM, Lau J (2007) Amodiaquine combined with sulfadoxine/pyrimethamine versus artemisinin-based combinations for the treatment of uncomplicated falciparum malaria in Africa: a meta-analysis. Trans R Soc Trop Med Hyg  101: 117–126.  <ul class="find" data-citedArticleID="1053878" data-doi="10.1016/j.trstmh.2006.07.001"><li><a href="http://dx.doi.org/10.1016/j.trstmh.2006.07.001" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Amodiaquine+combined+with+sulfadoxine%2Fpyrimethamine+versus+artemisinin-based+combinations+for+the+treatment+of+uncomplicated+falciparum+malaria+in+Africa%3A+a+meta-analysis." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Amodiaquine+combined+with+sulfadoxine%2Fpyrimethamine+versus+artemisinin-based+combinations+for+the+treatment+of+uncomplicated+falciparum+malaria+in+Africa%3A+a+meta-analysis.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">6.
              </span><a name="pone.0001578-Brasseur1" id="pone.0001578-Brasseur1"></a>Brasseur P, Guiguemde R, Diallo S, Guiyedi V, Kombila M, et al.  (1999) Amodiaquine remains effective for treating uncomplicated malaria in west and central Africa. Trans R Soc Trop Med Hyg  93: 645–650.  <ul class="find" data-citedArticleID="1053840" data-doi="10.1016/s0035-9203(99)90083-4"><li><a href="http://dx.doi.org/10.1016/s0035-9203(99)90083-4" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Amodiaquine+remains+effective+for+treating+uncomplicated+malaria+in+west+and+central+Africa." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Amodiaquine+remains+effective+for+treating+uncomplicated+malaria+in+west+and+central+Africa.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">7.
              </span><a name="pone.0001578-Gasasira1" id="pone.0001578-Gasasira1"></a>Gasasira AF, Dorsey G, Nzarubara B, Staedke SG, Nassali A, et al.  (2003) Comparative efficacy of aminoquinoline-antifolate combinations for the treatment of uncomplicated falciparum malaria in Kampala, Uganda. Am J Trop Med Hyg  68: 127–132.  <ul class="find" data-citedArticleID="1053858"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=Comparative+efficacy+of+aminoquinoline-antifolate+combinations+for+the+treatment+of+uncomplicated+falciparum+malaria+in+Kampala%2C+Uganda.&amp;auth=&amp;atitle=Comparative+efficacy+of+aminoquinoline-antifolate+combinations+for+the+treatment+of+uncomplicated+falciparum+malaria+in+Kampala%2C+Uganda." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Comparative+efficacy+of+aminoquinoline-antifolate+combinations+for+the+treatment+of+uncomplicated+falciparum+malaria+in+Kampala%2C+Uganda." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Comparative+efficacy+of+aminoquinoline-antifolate+combinations+for+the+treatment+of+uncomplicated+falciparum+malaria+in+Kampala%2C+Uganda.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">8.
              </span><a name="pone.0001578-Hatton1" id="pone.0001578-Hatton1"></a>Hatton CS, Peto TE, Bunch C, Pasvol G, Russell SJ, et al.  (1986) Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria. Lancet  1: 411–414.  <ul class="find" data-citedArticleID="1053862" data-doi="10.1016/s0140-6736(86)92371-8"><li><a href="http://dx.doi.org/10.1016/s0140-6736(86)92371-8" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Frequency+of+severe+neutropenia+associated+with+amodiaquine+prophylaxis+against+malaria." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Frequency+of+severe+neutropenia+associated+with+amodiaquine+prophylaxis+against+malaria.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">9.
              </span><a name="pone.0001578-Neftel1" id="pone.0001578-Neftel1"></a>Neftel KA, Woodtly W, Schmid M, Frick PG, Fehr J (1986) Amodiaquine induced agranulocytosis and liver damage. Br Med J (Clin Res Ed)  292: 721–723.  <ul class="find" data-citedArticleID="1053874" data-doi="10.1136/bmj.292.6522.721"><li><a href="http://dx.doi.org/10.1136/bmj.292.6522.721" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Amodiaquine+induced+agranulocytosis+and+liver+damage." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Amodiaquine+induced+agranulocytosis+and+liver+damage.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">10.
              </span><a name="pone.0001578-Olliaro1" id="pone.0001578-Olliaro1"></a>Olliaro P, Mussano P (2003) Amodiaquine for treating malaria. Cochrane Database Syst Rev CD000016.   <ul class="find" data-citedArticleID="1053880" data-doi="10.1002/14651858.cd000016"><li><a href="http://dx.doi.org/10.1002/14651858.cd000016" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Amodiaquine+for+treating+malaria." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Amodiaquine+for+treating+malaria.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">11.
              </span><a name="pone.0001578-Djimde1" id="pone.0001578-Djimde1"></a>Djimde AA, Dolo A, Ouattara A, Diakite S, Plowe CV, et al.  (2004) Molecular diagnosis of resistance to antimalarial drugs during epidemics and in war zones. J Infect Dis  190: 853–855.  <ul class="find" data-citedArticleID="1053846" data-doi="10.1086/422758"><li><a href="http://dx.doi.org/10.1086/422758" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Molecular+diagnosis+of+resistance+to+antimalarial+drugs+during+epidemics+and+in+war+zones." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Molecular+diagnosis+of+resistance+to+antimalarial+drugs+during+epidemics+and+in+war+zones.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">12.
              </span><a name="pone.0001578-Kublin1" id="pone.0001578-Kublin1"></a>Kublin JG, Cortese JF, Njunju EM, Mukadam RA, Wirima JJ, et al.  (2003) Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J Infect Dis  187: 1870–1875.  <ul class="find" data-citedArticleID="1053868" data-doi="10.1086/375419"><li><a href="http://dx.doi.org/10.1086/375419" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Reemergence+of+chloroquine-sensitive+Plasmodium+falciparum+malaria+after+cessation+of+chloroquine+use+in+Malawi." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Reemergence+of+chloroquine-sensitive+Plasmodium+falciparum+malaria+after+cessation+of+chloroquine+use+in+Malawi.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">13.
              </span><a name="pone.0001578-Plowe2" id="pone.0001578-Plowe2"></a>Plowe CV, Cortese JF, Djimde A, Nwanyanwu OC, Watkins WM, et al.  (1997) Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J Infect Dis  176: 1590–1596.  <ul class="find" data-citedArticleID="1053888" data-doi="10.1086/514159"><li><a href="http://dx.doi.org/10.1086/514159" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Mutations+in+Plasmodium+falciparum+dihydrofolate+reductase+and+dihydropteroate+synthase+and+epidemiologic+patterns+of+pyrimethamine-sulfadoxine+use+and+resistance." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Mutations+in+Plasmodium+falciparum+dihydrofolate+reductase+and+dihydropteroate+synthase+and+epidemiologic+patterns+of+pyrimethamine-sulfadoxine+use+and+resistance.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">14.
              </span><a name="pone.0001578-World2" id="pone.0001578-World2"></a>World Health Organisation (2003) Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria.   <a href="http://www.who.int/malaria/docs/ProtocolWHO.pdf">http://www.who.int/malaria/docs/Protocol​WHO.pdf</a>.  <ul class="find-nolinks"></ul></li><li><span class="label">15.
              </span><a name="pone.0001578-Cattamanchi1" id="pone.0001578-Cattamanchi1"></a>Cattamanchi A, Kyabayinze D, Hubbard A, Rosenthal PJ, Dorsey G (2003) Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of msp-1, msp-2, and glurp. Am J Trop Med Hyg  68: 133–139.  <ul class="find" data-citedArticleID="1053844"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=Distinguishing+recrudescence+from+reinfection+in+a+longitudinal+antimalarial+drug+efficacy+study%3A+comparison+of+results+based+on+genotyping+of+msp-1%2C+msp-2%2C+and+glurp.&amp;auth=&amp;atitle=Distinguishing+recrudescence+from+reinfection+in+a+longitudinal+antimalarial+drug+efficacy+study%3A+comparison+of+results+based+on+genotyping+of+msp-1%2C+msp-2%2C+and+glurp." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Distinguishing+recrudescence+from+reinfection+in+a+longitudinal+antimalarial+drug+efficacy+study%3A+comparison+of+results+based+on+genotyping+of+msp-1%2C+msp-2%2C+and+glurp." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Distinguishing+recrudescence+from+reinfection+in+a+longitudinal+antimalarial+drug+efficacy+study%3A+comparison+of+results+based+on+genotyping+of+msp-1%2C+msp-2%2C+and+glurp.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">16.
              </span><a name="pone.0001578-Kublin2" id="pone.0001578-Kublin2"></a>Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, et al.  (2002) Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis  185: 380–388.  <ul class="find" data-citedArticleID="1053870" data-doi="10.1086/338566"><li><a href="http://dx.doi.org/10.1086/338566" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Molecular+markers+for+failure+of+sulfadoxine-pyrimethamine+and+chlorproguanil-dapsone+treatment+of+Plasmodium+falciparum+malaria." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Molecular+markers+for+failure+of+sulfadoxine-pyrimethamine+and+chlorproguanil-dapsone+treatment+of+Plasmodium+falciparum+malaria.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">17.
              </span><a name="pone.0001578-Abuya1" id="pone.0001578-Abuya1"></a>Abuya TO, Mutemi W, Karisa B, Ochola SA, Fegan G, et al.  (2007) Use of over-the-counter malaria medicines in children and adults in three districts in Kenya: implications for private medicine retailer interventions. Malar J  6: 57.  <ul class="find" data-citedArticleID="1053836" data-doi="10.1186/1475-2875-6-57"><li><a href="http://dx.doi.org/10.1186/1475-2875-6-57" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Use+of+over-the-counter+malaria+medicines+in+children+and+adults+in+three+districts+in+Kenya%3A+implications+for+private+medicine+retailer+interventions." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Use+of+over-the-counter+malaria+medicines+in+children+and+adults+in+three+districts+in+Kenya%3A+implications+for+private+medicine+retailer+interventions.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">18.
              </span><a name="pone.0001578-Hawley1" id="pone.0001578-Hawley1"></a>Hawley SR, Bray PG, Park BK, Ward SA (1996) Amodiaquine accumulation in Plasmodium falciparum as a possible explanation for its superior antimalarial activity over chloroquine. Mol Biochem Parasitol  80: 15–25.  <ul class="find" data-citedArticleID="1053864" data-doi="10.1016/0166-6851(96)02655-2"><li><a href="http://dx.doi.org/10.1016/0166-6851(96)02655-2" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Amodiaquine+accumulation+in+Plasmodium+falciparum+as+a+possible+explanation+for+its+superior+antimalarial+activity+over+chloroquine." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Amodiaquine+accumulation+in+Plasmodium+falciparum+as+a+possible+explanation+for+its+superior+antimalarial+activity+over+chloroquine.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">19.
              </span><a name="pone.0001578-Dorsey1" id="pone.0001578-Dorsey1"></a>Dorsey G, Njama D, Kamya MR, Cattamanchi A, Kyabayinze D, et al.  (2002) Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial. Lancet  360: 2031–2038.  <ul class="find" data-citedArticleID="1053850" data-doi="10.1016/s0140-6736(02)12021-6"><li><a href="http://dx.doi.org/10.1016/s0140-6736(02)12021-6" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Sulfadoxine%2Fpyrimethamine+alone+or+with+amodiaquine+or+artesunate+for+treatment+of+uncomplicated+malaria%3A+a+longitudinal+randomised+trial." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Sulfadoxine%2Fpyrimethamine+alone+or+with+amodiaquine+or+artesunate+for+treatment+of+uncomplicated+malaria%3A+a+longitudinal+randomised+trial.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">20.
              </span><a name="pone.0001578-Rwagacondo1" id="pone.0001578-Rwagacondo1"></a>Rwagacondo CE, Niyitegeka F, Sarushi J, Karema C, Mugisha V, et al.  (2003) Efficacy of amodiaquine alone and combined with sulfadoxine-pyrimethamine and of sulfadoxine pyrimethamine combined with artesunate. Am J Trop Med Hyg  68: 743–747.  <ul class="find" data-citedArticleID="1053892"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=Efficacy+of+amodiaquine+alone+and+combined+with+sulfadoxine-pyrimethamine+and+of+sulfadoxine+pyrimethamine+combined+with+artesunate.&amp;auth=&amp;atitle=Efficacy+of+amodiaquine+alone+and+combined+with+sulfadoxine-pyrimethamine+and+of+sulfadoxine+pyrimethamine+combined+with+artesunate." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Efficacy+of+amodiaquine+alone+and+combined+with+sulfadoxine-pyrimethamine+and+of+sulfadoxine+pyrimethamine+combined+with+artesunate." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Efficacy+of+amodiaquine+alone+and+combined+with+sulfadoxine-pyrimethamine+and+of+sulfadoxine+pyrimethamine+combined+with+artesunate.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">21.
              </span><a name="pone.0001578-Watkins1" id="pone.0001578-Watkins1"></a>Watkins WM, Mosobo M (1993) Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life. Trans R Soc Trop Med Hyg  87: 75–78.  <ul class="find" data-citedArticleID="1053896" data-doi="10.1016/0035-9203(93)90431-o"><li><a href="http://dx.doi.org/10.1016/0035-9203(93)90431-o" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Treatment+of+Plasmodium+falciparum+malaria+with+pyrimethamine-sulfadoxine%3A+selective+pressure+for+resistance+is+a+function+of+long+elimination+half-life." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Treatment+of+Plasmodium+falciparum+malaria+with+pyrimethamine-sulfadoxine%3A+selective+pressure+for+resistance+is+a+function+of+long+elimination+half-life.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">22.
              </span><a name="pone.0001578-Happi1" id="pone.0001578-Happi1"></a>Happi CT, Gbotosho GO, Folarin OA, Bolaji OM, Sowunmi A, et al.  (2006) Association between mutations in Plasmodium falciparum chloroquine resistance transporter and P. falciparum multidrug resistance 1 genes and in vivo amodiaquine resistance in P. falciparum malaria-infected children in Nigeria. Am J Trop Med Hyg  75: 155–161.  <ul class="find" data-citedArticleID="1053860" data-doi="10.1007/s00436-006-0246-4"><li><a href="http://dx.doi.org/10.1007/s00436-006-0246-4" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Association+between+mutations+in+Plasmodium+falciparum+chloroquine+resistance+transporter+and+P.+falciparum+multidrug+resistance+1+genes+and+in+vivo+amodiaquine+resistance+in+P.+falciparum+malaria-infected+children+in+Nigeria." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Association+between+mutations+in+Plasmodium+falciparum+chloroquine+resistance+transporter+and+P.+falciparum+multidrug+resistance+1+genes+and+in+vivo+amodiaquine+resistance+in+P.+falciparum+malaria-infected+children+in+Nigeria.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">23.
              </span><a name="pone.0001578-Humphreys1" id="pone.0001578-Humphreys1"></a>Humphreys GS, Merinopoulos I, Ahmed J, Whitty CJ, Mutabingwa TK, et al.  (2007) Amodiaquine and artemether-lumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria. Antimicrob Agents Chemother  51: 991–997.  <ul class="find" data-citedArticleID="1053866" data-doi="10.1128/aac.00875-06"><li><a href="http://dx.doi.org/10.1128/aac.00875-06" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Amodiaquine+and+artemether-lumefantrine+select+distinct+alleles+of+the+Plasmodium+falciparum+mdr1+gene+in+Tanzanian+children+treated+for+uncomplicated+malaria." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Amodiaquine+and+artemether-lumefantrine+select+distinct+alleles+of+the+Plasmodium+falciparum+mdr1+gene+in+Tanzanian+children+treated+for+uncomplicated+malaria.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">24.
              </span><a name="pone.0001578-Nsobya1" id="pone.0001578-Nsobya1"></a>Nsobya SL, Dokomajilar C, Joloba M, Dorsey G, Rosenthal PJ (2007) Resistance-Mediating Plasmodium falciparum pfcrt and pfmdr1 Alleles after Treatment with Artesunate-Amodiaquine in Uganda. Antimicrob Agents Chemother  51: 3023–3025.  <ul class="find" data-citedArticleID="1053876" data-doi="10.1128/aac.00012-07"><li><a href="http://dx.doi.org/10.1128/aac.00012-07" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Resistance-Mediating+Plasmodium+falciparum+pfcrt+and+pfmdr1+Alleles+after+Treatment+with+Artesunate-Amodiaquine+in+Uganda." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Resistance-Mediating+Plasmodium+falciparum+pfcrt+and+pfmdr1+Alleles+after+Treatment+with+Artesunate-Amodiaquine+in+Uganda.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">25.
              </span><a name="pone.0001578-Zongo1" id="pone.0001578-Zongo1"></a>Zongo I, Dorsey G, Rouamba N, Tinto H, Dokomajilar C, et al.  (2007) Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial. Lancet  369: 491–498.  <ul class="find" data-citedArticleID="1053902" data-doi="10.1016/s0140-6736(07)60236-0"><li><a href="http://dx.doi.org/10.1016/s0140-6736(07)60236-0" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Artemether-lumefantrine+versus+amodiaquine+plus+sulfadoxine-pyrimethamine+for+uncomplicated+falciparum+malaria+in+Burkina+Faso%3A+a+randomised+non-inferiority+trial." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Artemether-lumefantrine+versus+amodiaquine+plus+sulfadoxine-pyrimethamine+for+uncomplicated+falciparum+malaria+in+Burkina+Faso%3A+a+randomised+non-inferiority+trial.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">26.
              </span><a name="pone.0001578-Dokomajilar1" id="pone.0001578-Dokomajilar1"></a>Dokomajilar C, Nsobya SL, Greenhouse B, Rosenthal PJ, Dorsey G (2006) Selection of Plasmodium falciparum pfmdr1 alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemic. Antimicrob Agents Chemother  50: 1893–1895.  <ul class="find" data-citedArticleID="1053848" data-doi="10.1128/aac.50.5.1893-1895.2006"><li><a href="http://dx.doi.org/10.1128/aac.50.5.1893-1895.2006" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Selection+of+Plasmodium+falciparum+pfmdr1+alleles+following+therapy+with+artemether-lumefantrine+in+an+area+of+Uganda+where+malaria+is+highly+endemic." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Selection+of+Plasmodium+falciparum+pfmdr1+alleles+following+therapy+with+artemether-lumefantrine+in+an+area+of+Uganda+where+malaria+is+highly+endemic.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">27.
              </span><a name="pone.0001578-Sisowath1" id="pone.0001578-Sisowath1"></a>Sisowath C, Stromberg J, Martensson A, Msellem M, Obondo C, et al.  (2005) In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem). J Infect Dis  191: 1014–1017.  <ul class="find" data-citedArticleID="1053894" data-doi="10.1086/427997"><li><a href="http://dx.doi.org/10.1086/427997" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=In+vivo+selection+of+Plasmodium+falciparum+pfmdr1+86N+coding+alleles+by+artemether-lumefantrine+%28Coartem%29." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22In+vivo+selection+of+Plasmodium+falciparum+pfmdr1+86N+coding+alleles+by+artemether-lumefantrine+%28Coartem%29.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">28.
              </span><a name="pone.0001578-Duraisingh1" id="pone.0001578-Duraisingh1"></a>Duraisingh MT, Roper C, Walliker D, Warhurst DC (2000) Increased sensitivity to the antimalarials mefloquine and artemisinin is conferred by mutations in the pfmdr1 gene of Plasmodium falciparum. Mol Microbiol  36: 955–961.  <ul class="find" data-citedArticleID="1053854" data-doi="10.1046/j.1365-2958.2000.01914.x"><li><a href="http://dx.doi.org/10.1046/j.1365-2958.2000.01914.x" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Increased+sensitivity+to+the+antimalarials+mefloquine+and+artemisinin+is+conferred+by+mutations+in+the+pfmdr1+gene+of+Plasmodium+falciparum." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Increased+sensitivity+to+the+antimalarials+mefloquine+and+artemisinin+is+conferred+by+mutations+in+the+pfmdr1+gene+of+Plasmodium+falciparum.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">29.
              </span><a name="pone.0001578-Alker1" id="pone.0001578-Alker1"></a>Alker AP, Mwapasa V, Purfield A, Rogerson SJ, Molyneux ME, et al.  (2005) Mutations associated with sulfadoxine-pyrimethamine and chlorproguanil resistance in Plasmodium falciparum isolates from Blantyre, Malawi. Antimicrob Agents Chemother  49: 3919–3921.  <ul class="find" data-citedArticleID="1053838" data-doi="10.1128/aac.49.9.3919-3921.2005"><li><a href="http://dx.doi.org/10.1128/aac.49.9.3919-3921.2005" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Mutations+associated+with+sulfadoxine-pyrimethamine+and+chlorproguanil+resistance+in+Plasmodium+falciparum+isolates+from+Blantyre%2C+Malawi." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Mutations+associated+with+sulfadoxine-pyrimethamine+and+chlorproguanil+resistance+in+Plasmodium+falciparum+isolates+from+Blantyre%2C+Malawi.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">30.
              </span><a name="pone.0001578-PhillipsHoward1" id="pone.0001578-PhillipsHoward1"></a>Phillips-Howard PA, West LJ (1990) Serious adverse drug reactions to pyrimethamine-sulphadoxine, pyrimethamine-dapsone and to amodiaquine in Britain. J R Soc Med  83: 82–85.  <ul class="find" data-citedArticleID="1053884"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=Serious+adverse+drug+reactions+to+pyrimethamine-sulphadoxine%2C+pyrimethamine-dapsone+and+to+amodiaquine+in+Britain.&amp;auth=&amp;atitle=Serious+adverse+drug+reactions+to+pyrimethamine-sulphadoxine%2C+pyrimethamine-dapsone+and+to+amodiaquine+in+Britain." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Serious+adverse+drug+reactions+to+pyrimethamine-sulphadoxine%2C+pyrimethamine-dapsone+and+to+amodiaquine+in+Britain." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Serious+adverse+drug+reactions+to+pyrimethamine-sulphadoxine%2C+pyrimethamine-dapsone+and+to+amodiaquine+in+Britain.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">31.
              </span><a name="pone.0001578-Douer1" id="pone.0001578-Douer1"></a>Douer D, Schwartz E, Shaked N, Ramot B (1985) Amodiaquine-induced agranulocytosis: drug inhibition of myeloid colonies in the presence of patient's serum. Isr J Med Sci  21: 331–334.  <ul class="find" data-citedArticleID="1053852"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=Amodiaquine-induced+agranulocytosis%3A+drug+inhibition+of+myeloid+colonies+in+the+presence+of+patient%27s+serum.&amp;auth=&amp;atitle=Amodiaquine-induced+agranulocytosis%3A+drug+inhibition+of+myeloid+colonies+in+the+presence+of+patient%27s+serum." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Amodiaquine-induced+agranulocytosis%3A+drug+inhibition+of+myeloid+colonies+in+the+presence+of+patient%27s+serum." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Amodiaquine-induced+agranulocytosis%3A+drug+inhibition+of+myeloid+colonies+in+the+presence+of+patient%27s+serum.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">32.
              </span><a name="pone.0001578-Carr1" id="pone.0001578-Carr1"></a>Carr R (1986) Neutropenia and prophylactic amodiaquine. Lancet  1: 556.  <ul class="find" data-citedArticleID="1053842" data-doi="10.1016/s0140-6736(86)90908-6"><li><a href="http://dx.doi.org/10.1016/s0140-6736(86)90908-6" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Neutropenia+and+prophylactic+amodiaquine." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Neutropenia+and+prophylactic+amodiaquine.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">33.
              </span><a name="pone.0001578-Rhodes1" id="pone.0001578-Rhodes1"></a>Rhodes EG, Ball J, Franklin IM (1986) Amodiaquine induced agranulocytosis: inhibition of colony growth in bone marrow by antimalarial agents. Br Med J (Clin Res Ed)  292: 717–718.  <ul class="find" data-citedArticleID="1053890" data-doi="10.1136/bmj.292.6522.717"><li><a href="http://dx.doi.org/10.1136/bmj.292.6522.717" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Amodiaquine+induced+agranulocytosis%3A+inhibition+of+colony+growth+in+bone+marrow+by+antimalarial+agents." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Amodiaquine+induced+agranulocytosis%3A+inhibition+of+colony+growth+in+bone+marrow+by+antimalarial+agents.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">34.
              </span><a name="pone.0001578-Ellis1" id="pone.0001578-Ellis1"></a>Ellis ME, Steed AJ, Addison GM (1987) Neutropenia associated with dual antimalarial chemoprophylaxis--use of bone-marrow culture as an aid in further drug management. J Infect  15: 147–152.  <ul class="find" data-citedArticleID="1053856" data-doi="10.1016/s0163-4453(87)93130-6"><li><a href="http://dx.doi.org/10.1016/s0163-4453(87)93130-6" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Neutropenia+associated+with+dual+antimalarial+chemoprophylaxis--use+of+bone-marrow+culture+as+an+aid+in+further+drug+management." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Neutropenia+associated+with+dual+antimalarial+chemoprophylaxis--use+of+bone-marrow+culture+as+an+aid+in+further+drug+management.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li></ol></div>

  </div>

      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001578.XML" value="83409"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001578.PDF" value="299766"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001578.g001.PNG_L" value="87412"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001578.g001.PNG_M" value="42218"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001578.g001.PNG_S" value="7863"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001578.g001.TIF" value="188862"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001578.g001.PNG_I" value="19932"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001578.t001.PNG_L" value="198142"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001578.t001.PNG_M" value="112568"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001578.t001.PNG_S" value="12404"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001578.t001.TIF" value="912808"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001578.t001.PNG_I" value="34116"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001578.t002.PNG_L" value="113303"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001578.t002.PNG_M" value="66307"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001578.t002.PNG_S" value="10182"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001578.t002.TIF" value="513442"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001578.t002.PNG_I" value="20104"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001578.g002.PNG_L" value="79189"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001578.g002.PNG_M" value="31593"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001578.g002.PNG_S" value="9873"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001578.g002.TIF" value="203110"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001578.g002.PNG_I" value="10480"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001578.g003.PNG_L" value="268657"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001578.g003.PNG_M" value="37165"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001578.g003.PNG_S" value="9683"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001578.g003.TIF" value="690346"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001578.g003.PNG_I" value="11694"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001578.s001.DOC" value="58880"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001578.s002.DOC" value="72704"/>

</div>
<div class="sidebar">

  <div class="article-actions cf">
      <div class="download">
        <span class="btn"><a href="/article/fetchObject.action?uri=info%3Adoi%2F10.1371%2Fjournal.pone.0001578&amp;representation=PDF" title="Download" target="_blank">Download PDF</a></span>
      </div>
      <div class="btn-reveal dropdown">
        <div class="dropdown-icon">
          <span class="btn">&nbsp;</span>
        </div>

        <div class="content">
          <ul class="bullet">
            <li><a href="/article/citationList.action?articleURI=info%3Adoi%2F10.1371%2Fjournal.pone.0001578" title="Download citations">Citation</a></li>
            <li><a href="/article/fetchObjectAttachment.action?uri=info%3Adoi%2F10.1371%2Fjournal.pone.0001578&amp;representation=XML" title="Download article XML">XML</a></li>
          </ul>
        </div>
      </div> <!-- end btn-reveal dropdown-->


    <div class="btn-reveal flt-l">
        <span class="btn">Print</span>
        <div class="content">
            <ul class="bullet">
                <li id="print-article"><a href="#" onclick="if(typeof(_gaq) != 'undefined'){ _gaq.push(['_trackEvent','Article', 'Print', 'Click']); } window.print(); return false;" title="Print Article">Print article</a></li>
                <li>
                  <a href="https://www.odysseypress.com/onlinehost/reprint_order.php?type=A&page=0&journal=7&doi=10.1371/journal.pone.0001578&volume=&issue=&title=Sulfadoxine-Pyrimethamine–Based Combinations for Malaria: A Randomised Blinded Trial to Compare Efficacy, Safety and Selection of Resistance in Malawi&author_name=David%20J.%20Bell%2C%20Suzgo%20K.%20Nyirongo%2C%20Mavuto%20Mukaka%2C%20Ed%20E.%20Zijlstra%2C%20Christopher%20V.%20Plowe%2C%20Malcolm%20E.%20Molyneux%2C%20Steve%20A.%20Ward%2C%20Peter%20A.%20Winstanley&start_page=1&end_page=8" title="Odyssey Press">EzReprint</a>
                </li>
            </ul>
        </div>
    </div>

    <div class="btn-reveal flt-r">
        <span class="btn">Share</span>
        <div class="content">
            <ul class="social">
                <li><a href="http://www.reddit.com/submit?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0001578" target="_blank" title="Submit to Reddit"><img src="/images/icon.reddit.16.png" width="16" height="16" alt="Reddit">Reddit</a></li>

                <li><a href="https://plus.google.com/share?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0001578" target="_blank" title="Share on Google+"><img src="/images/icon.gplus.16.png" width="16" height="16" alt="Google+">Google+</a></li>

                <li><a href="http://www.stumbleupon.com/submit?url=http%3A%2F%2Fwww.plosone.org%2Farticle%2Finfo%253Adoi%252F10.1371%252Fjournal.pone.0001578" target="_blank" title="Add to StumbleUpon"><img src="/images/icon.stumble.16.png" width="16" height="16" alt="StumbleUpon">StumbleUpon</a></li>

                <li><a href="http://www.facebook.com/share.php?u=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0001578&amp;t=Sulfadoxine-Pyrimethamine%E2%80%93Based%20Combinations%20for%20Malaria%3A%20A%20Randomised%20Blinded%20Trial%20to%20Compare%20Efficacy%2C%20Safety%20and%20Selection%20of%20Resistance%20in%20Malawi" target="_blank" title="Share on Facebook"><img src="/images/icon.fb.16.png" width="16" height="16" alt="Facebook">Facebook</a></li>

                <li><a href="http://www.linkedin.com/shareArticle?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0001578&title=Sulfadoxine-Pyrimethamine%E2%80%93Based%20Combinations%20for%20Malaria%3A%20A%20Randomised%20Blinded%20Trial%20to%20Compare%20Efficacy%2C%20Safety%20and%20Selection%20of%20Resistance%20in%20Malawi&summary=Checkout%20this%20article%20I%20found%20at%20PLOS" target="_blank" title="Add to LinkedIn"><img src="/images/icon.linkedin.16.png" width="16" height="16" alt="Mendeley">LinkedIn</a></li>

                <li><a href="http://www.citeulike.org/posturl?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0001578&amp;title=Sulfadoxine-Pyrimethamine%E2%80%93Based%20Combinations%20for%20Malaria%3A%20A%20Randomised%20Blinded%20Trial%20to%20Compare%20Efficacy%2C%20Safety%20and%20Selection%20of%20Resistance%20in%20Malawi" target="_blank" title="Add to CiteULike"><img src="/images/icon.cul.16.png" width="16" height="16" alt="CiteULike">CiteULike</a></li>

                <li><a href="http://www.mendeley.com/import/?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0001578" target="_blank" title="Add to Mendeley"><img src="/images/icon.mendeley.16.png" width="16" height="16" alt="Mendeley">Mendeley</a></li>

                <li><a href="https://www.pubchase.com/library?add_aid=10.1371%2Fjournal.pone.0001578&amp;source=plos" target="_blank" title="Add to PubChase"><img src="/images/icon.pc.16.png" width="16" height="16" alt="PubChase">PubChase</a></li>


                <script type="text/javascript">
                    // replace tweet with one that's pre-shortened to 140 chars
                    function truncateTweetText() {
                        var twtTitle = 'Sulfadoxine-Pyrimethamine–Based Combinations for Malaria: A Randomised Blinded Trial to Compare Efficacy, Safety and Selection of Resistance in Malawi';
                        var twtUrl = 'http://dx.plos.org/10.1371/journal.pone.0001578';
                        // all URLs posted to twitter get auto-shortened to 20 chars.
                        var maxLength = 140 - (20 + 1);
                        // truncate the title to include space for twtTag and ellipsis (here, 10 = tag length + space + ellipsis)
                        if (twtTitle.length > maxLength) { twtTitle = twtTitle.substr(0, (maxLength - 10)) + '...'; }
                        // set the href to use the shortened tweet
                        $('#twitter-share-link').prop('href', 'http://twitter.com/intent/tweet?text=' + encodeURIComponent('#PLOSONE: ' + twtTitle + ' ' + twtUrl));
                    }
                </script>
                <li><a href="http://twitter.com/intent/tweet?text=#PLOSONE%3A%20Sulfadoxine-Pyrimethamine%E2%80%93Based%20Combinations%20for%20Malaria%3A%20A%20Randomised%20Blinded%20Trial%20to%20Compare%20Efficacy%2C%20Safety%20and%20Selection%20of%20Resistance%20in%20Malawi http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0001578" onclick="truncateTweetText();" target="_blank" title="Share on Twitter" id="twitter-share-link"><img src="/images/icon.twtr.16.png" width="16" height="16" alt="Twitter">Twitter</a></li>

                <li><a href="/article/email/info%3Adoi%2F10.1371%2Fjournal.pone.0001578" title="Email this article"><img src="/images/icon.email.16.png" width="16" height="16" alt="Email">Email</a></li>
            </ul>
        </div>
    </div><!--end btn-reveal flt-r-->
</div><!-- end article-actions-->

<!-- begin Crossmark -->

<a id="open-crossmark" href="#" style="margin-top: -28px; display:block"><img style="border: 0; display: none;
 padding: 10px 0 18px 0;"  id="crossmark-icon" src="/images/logo-crossmark-bw.png" /></a>
<div id="crossmark-dialog" style="display: none;" title="">
    <!-- the external CrossMark data is loaded inside this iframe -->
    <iframe id="crossmark-dialog-frame" frameborder="0"></iframe>
</div>

<!-- end crossmark -->


<div class="block" id="subject-area-sidebar-block">
    <div class="header">
        <h3>Subject Areas</h3><div title="More information" id="subject-area-sidebar-block-help-icon"><img align="right"
                                                                                                           alt="info" src="/images/button_info.png"/><div id="subject-area-sidebar-block-help"><img align="right"
                                                                                                                                                                                                    src="/images/button_info.png"/><p>
        <b>We want your feedback.</b> Do these subject areas make sense for this article? If not, click the flag
        next to the incorrect subject area and we will review it. Thanks for your help!
    </p></div></div>
    </div>


    <ul id="subject-area-sidebar-list">















          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Children%22" title="Search for articles in the subject area:'Children'"><div class="flagText">Children</div></a>
              <div data-categoryid="40327" data-articleid="25982"
                   data-categoryname="Children"
                   class="flagImage" title="Flag 'Children' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Malaria%22" title="Search for articles in the subject area:'Malaria'"><div class="flagText">Malaria</div></a>
              <div data-categoryid="47353" data-articleid="25982"
                   data-categoryname="Malaria"
                   class="flagImage" title="Flag 'Malaria' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Malarial+parasites%22" title="Search for articles in the subject area:'Malarial parasites'"><div class="flagText">Malarial parasites</div></a>
              <div data-categoryid="42885" data-articleid="25982"
                   data-categoryname="Malarial parasites"
                   class="flagImage" title="Flag 'Malarial parasites' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Malawi%22" title="Search for articles in the subject area:'Malawi'"><div class="flagText">Malawi</div></a>
              <div data-categoryid="40965" data-articleid="25982"
                   data-categoryname="Malawi"
                   class="flagImage" title="Flag 'Malawi' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Mutation%22" title="Search for articles in the subject area:'Mutation'"><div class="flagText">Mutation</div></a>
              <div data-categoryid="31809" data-articleid="25982"
                   data-categoryname="Mutation"
                   class="flagImage" title="Flag 'Mutation' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Neutrophils%22" title="Search for articles in the subject area:'Neutrophils'"><div class="flagText">Neutrophils</div></a>
              <div data-categoryid="40487" data-articleid="25982"
                   data-categoryname="Neutrophils"
                   class="flagImage" title="Flag 'Neutrophils' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Parasitic+diseases%22" title="Search for articles in the subject area:'Parasitic diseases'"><div class="flagText">Parasitic diseases</div></a>
              <div data-categoryid="2663" data-articleid="25982"
                   data-categoryname="Parasitic diseases"
                   class="flagImage" title="Flag 'Parasitic diseases' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Prophylaxis%22" title="Search for articles in the subject area:'Prophylaxis'"><div class="flagText">Prophylaxis</div></a>
              <div data-categoryid="24723" data-articleid="25982"
                   data-categoryname="Prophylaxis"
                   class="flagImage" title="Flag 'Prophylaxis' as inappropriate"></div>
          </li>
    </ul>
</div>

<div class="ad">
    <div class="title">Advertisement</div>






  <iframe id='a0852f54' name='a0852f54'
    src='http://ads.plos.org/www/delivery/afr.php?zoneid=381&amp;cb=4444'
    frameborder='0' scrolling='no' width='160' height='600'>
    <a href='http://ads.plos.org/www/delivery/ck.php?n=a0852f54&amp;cb=7026'
      target='_top'><img src='http://ads.plos.org/www/delivery/avw.php?zoneid=381&amp;cb=1385&amp;n=a0852f54'
      border='0' alt=''/>
    </a>
  </iframe>



</div>

<div id="twitter-alm-timeline" class="twitter-alm-timeline"></div>


</div><!-- sidebar -->
    </div>
  </div>
</div>
<script src="http://wl.figshare.com/static/p_widget.js" type="text/javascript"></script><div id="pageftr">
  <div class="ftr-cols cf">
    <div class="col col-1">
      <img src="/images/logo-plos-footer.png" alt="PLOS Logo" class="logo" />
      <p><a href="/static/releaseNotes">Ambra 2.9.16</a> Managed Colocation provided <br />by <a href="http://www.isc.org/">Internet Systems Consortium</a>.<p>
      <div class="nav nav-aux">
        <a href="/static/privacy">Privacy Policy</a> |
        <a href="/static/terms">Terms of Use</a> |
        <a href="http://www.plos.org/advertise/">Advertise</a> |
        <a href="http://www.plos.org/about/media-inquiries/">Media Inquiries</a>
      </div>
    </div>
    <div class="col col-2">
      <p><a href="http://www.plos.org/publications/journals/">Publications</a></p>
      <div class="nav">
        <ul>
          <li><a href="http://www.plosbiology.org">PLOS Biology</a></li>
          <li><a href="http://www.plosmedicine.org">PLOS Medicine</a></li>
          <li><a href="http://www.ploscompbiol.org">PLOS Computational Biology</a></li>
          <li><a href="http://currents.plos.org">PLOS Currents</a></li>
          <li><a href="http://www.plosgenetics.org">PLOS Genetics</a></li>
          <li><a href="http://www.plospathogens.org">PLOS Pathogens</a></li>
          <li><a href="http://www.plosone.org">PLOS ONE</a></li>
          <li><a href="http://www.plosntds.org">PLOS Neglected Tropical Diseases</a></li>
        </ul>
      </div>
    </div>
    <div class="col col-3">
      <div class="nav">
        <p><a href="http://www.plos.org">plos.org</a></p>
        <p><a href="http://blogs.plos.org">Blogs</a></p>
        <p><a href="http://www.ploscollections.org">Collections</a></p>
        <p><a href="/feedback/new">Send us feedback</a></p>

        <p>California (US) corporation #C2354500, based in San Francisco</p>
      </div>
    </div>
  </div>
</div><!-- pageftr -->

</div><!-- end page-wrap, this div is in header.ftl -->
<script type="text/javascript" src="/javascript/jquery-1.8.1-min.js?v=Tm7VCOzZz3lE03ghpkS6SWkHbyI"></script>
<script type="text/javascript" src="/javascript/ga-min.js?v=lNQ4gt8QcPDatjsdOFl_FGpPhLY"></script>
<script type="text/javascript" src="/javascript/jquery.hoverIntent-min.js?v=mRiGNYY9cIXxVb8u0K_MdW7hHnc"></script>
<script type="text/javascript" src="/javascript/jquery.placeholder-min.js?v=21Pn56Ur9h1N4K4VZDa0nqI3Pxo"></script>
<script type="text/javascript" src="/javascript/jquery.jsonp-2.4.0-min.js?v=lqTpzoHfSq3I5Ygo01qq5WankEo"></script>
<script type="text/javascript" src="/javascript/jquery-ui-1.9.2.custom-min.js?v=raSSlfNO0YsV5uUpAKmTB9n5VTc"></script>
<script type="text/javascript" src="/javascript/jquery.tooltip-min.js?v=cw+6Smh+mdryIA25xvqIvHMrnZM"></script>
<script type="text/javascript" src="/javascript/jquery.uniform-min.js?v=kYUAnX6W2W_2fK3RIuQ2m_YFG9U"></script>
<script type="text/javascript" src="/javascript/jquery.pjax-min.js?v=939kLBjL5_YKbx71T1RHjYaD4l8"></script>
<script type="text/javascript" src="/javascript/imagesloaded-min.js?v=XeuAp8Gc3mvQUo+wZCSF8ttPwvw"></script>
<script type="text/javascript" src="/javascript/figviewer-min.js?v=yPUa0sUQ_iHkI+IRv2i9bjyZJFo"></script>
<script type="text/javascript" src="/javascript/global-min.js?v=0Q3PwjeaWtXYDnqIsQvnL_ou0qs"></script>
<script type="text/javascript" src="/javascript/jquery.touchswipe-min.js?v=huaek_e6HqTduvCNAN91dJolTyw"></script>
<script type="text/javascript" src="/javascript/jquery.base64-min.js?v=VwV1zeVqKZj5FCAdlK0q5NRxbBg"></script>
<script type="text/javascript" src="/javascript/alm-min.js?v=Y5gm6B0b4Kx2YHNObNrgEeBgXlY"></script>
<script type="text/javascript" src="/javascript/taxonomy-browser-min.js?v=vBVMuDMYkGJCXIUxLe35GoyiJNw"></script>
<script type="text/javascript" src="/javascript/jquery.filterize-min.js?v=j0ZKVnHyk2nhFy8eIuNJkp7xaM0"></script>
<script type="text/javascript" src="/javascript/plosone-min.js?v=TK4H4arL_XBSwwJq+K1N3kqYfAI"></script>
<script type="text/javascript" src="/javascript/twitter-min.js?v=xKgcxLsQFXy+at1ao1NVke8nFlM"></script>
<script type="text/javascript" src="/javascript/crossmark.1.4-min.js?v=3FO4k0SjwTaGNnKGNSqthar1080"></script>
<script type="text/javascript">
  var _sf_async_config={uid:16579,domain:"plosone.org"};
  (function(){
    function loadChartbeat() {
      window._sf_endpt=(new Date()).getTime();
      var e = document.createElement('script');
      e.setAttribute('language', 'javascript');
      e.setAttribute('type', 'text/javascript');
      e.setAttribute('src',
          (("https:" == document.location.protocol) ? "https://a248.e.akamai.net/chartbeat.download.akamai.com/102508/" : "http://static.chartbeat.com/") +
              "js/chartbeat.js");
      document.body.appendChild(e);
    }
    var oldonload = window.onload;
    window.onload = (typeof window.onload != 'function') ?
        loadChartbeat : function() { oldonload(); loadChartbeat(); };
  })();
</script>
<!-- <script type="application/javascript" src="http://crossmark.crossref.org/javascripts/v1.3/crossmark.min.js"></script> -->

</body>
</html>
